For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and Attruby represents a significant advancement . These innovative therapies protect the transthyretin protein, preventing its damaging build-up and alleviating the burden of the illness. Patients are now seeing positive